Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
about
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
description
scientific article published on 15 June 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@en
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@nl
type
label
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@en
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@nl
prefLabel
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@en
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@nl
P2093
P2860
P356
P1476
Guselkumab, an anti-interleuki ...... lind, placebo-controlled study
@en
P2093
Hidemi Nakagawa
Mamitaro Ohtsuki
Richuan Zheng
Ryosuke Goto
P2860
P304
P356
10.1111/1346-8138.14504
P407
P577
2018-06-15T00:00:00Z